Position Title
Postdoctoral Fellow
Dr Cassandra (Cassie) Hatzipantelis is a postdoctoral research fellow with a keen interest in understanding, developing, and advancing novel therapeutic agents for the treatment of neuropsychiatric disorders. They have a PhD in Drug Discovery Biology from Monash University, Australia where she studied the efficacy and molecular mechanisms of a novel class therapeutics to treat schizophrenia. Her work during her PhD was critical to the establishment of the Neuromedicines Discovery Centre spin-out biotech company, Phrenix Therapeutics, wherein the pipelines and frameworks Cassie spearheaded the development of are currently in use to design and test novel, safe and effective antipsychotic and procognitive agents. Now in the Olson Lab and as a research fellow for the IPN, Cassie works on various projects related to the pharmacology of psychedelic drugs and their role in neurophysiology, neuropsychiatric pathophysiology, and in the treatment of neuropsychiatric disorders.
- Monash University's Institute of Pharmaceutical Sciences - Ph.D., Drug Discovery Biology (2022)
- Monash University - Bachelor of Pharmaceutical Sciences (advanced)
- First Class Honours (Australian equivalent to Summa Cum Laude)
- Neuropsychopharmacology
- CNS Drug Discovery
- GPCR Molecular Pharmacology
- Orphan GPCRs
- Hatzipantelis CJ, Olson DE. The Effects of Psychedelics on Neuronal Physiology. (2024). Annu. Rev. Physiol.
- Hatzipantelis CJ, Langiu M, Vandekolk TH, Pierce TL, Nithianantharajah J, et al. Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia. (2020). ACS Pharmacol. Transl. Sci.
- Hatzipantelis CJ, Lu Y, Spark DL, Langmead CJ, Stewart GD. β-Arrestin-2-Dependent Mechanism of GPR52 Signaling in Frontal Cortical Neurons. (2020). ACS Chem. Neurosci.
- Spark DL, Vermeulen MH, de la Fuente Gonzalez RA, Hatzipantelis CJ, Rueda P, Sepehrizadeh T, De Veer M, Mannoury la Cour C, Fornito A, Langiu M, Stewart GD, Nithianantharajah J, Langmead CJ. Gpr88 Deletion Impacts Motivational Control Without Overt Disruptions to Striatal Dopamine. (2022). BP:GOS
- Lu Y, Hatzipantelis CJ, Langmead CJ, Stewart GD. Molecular insights into orphan G protein-coupled receptors relevant to schizophrenia. (2023). Br. J. Pharmacol.
- Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT)
- Students of Brain Research Network
- Biological Psychiatry Australia (BPA)